NCT02902016

Modulation of Lactase Expression by a New PPARgamma Ligand in Duodenal Biopsies

Modulation of Lactase Expression by a New Synthetic PPARgamma Ligand in Ex-vivo Cultures of Duodenal Biopsies

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: University Hospital, Lille · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

This study is designed to assess the effect of a new PPARgamma modulator on the expression and activity of the lactase enzyme in human intestinal epithelial cells. Based on their previous experimental results, the investigators hypothesized that modulating intestinal PPARgamma activity is a new pharmacological mechanism allowing the control of lactase expression and activity in the gut

Conditions

• Lactose Intolerance

Interventions

Type	Name	Description
DRUG	GED	Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).

Timeline

• Start date: 2015-07-16
• Primary completion: 2017-09-01
• Completion: 2017-09-01
• First posted: 2016-09-15
• Last updated: 2018-10-17

Locations

1 site across 1 country: France